Skip to main content
SpringerLink
Log in

Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine

  • Research Article
  • Theme: Towards Integrated ADME Prediction: Past, Present, and Future Directions
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

The purpose of this study was to develop simulation and modeling methods for the evaluation of pharmacokinetics when intestinal influx and efflux transporters are involved in gastrointestinal absorption. The advanced compartmental absorption and transit (ACAT) model as part of the computer program GastroPlus™ was used to simulate the absorption and pharmacokinetics of valacyclovir, gabapentin, and talinolol. Each of these drugs is a substrate for an influx or efflux transporter and all show nonlinear dose dependence within the normal therapeutic range. These simulations incorporated the experimentally derived gastrointestinal distributions of transporter expression levels for oligopeptide transporters PepT1 and HPT1 (valacyclovir); System L-amino acid transporter LAT2 and organic cation transporter OCTN1 (gabapentin); and organic anion transporter (OATP1A2) and P-glycoprotein (talinolol). By assuming a uniform distribution of oligopeptide transporter and by application of the in vitro K m value for valacyclovir, the simulations accurately reproduced the experimental nonlinear dose dependence. For gabapentin, LAT2 distribution produced simulation results that were much more accurate than OCTN1 distributions. For talinolol, an influx transporter distribution for OATP1A2 and the efflux transporter P-glycoprotein distributed with increasing expression in the distal small intestine produced the best results. The physiological characteristics of the small and large intestines used in the ACAT model were able to accurately account for the positional and temporal changes in concentration and carrier-mediated transport of the three drugs included in this study. The ACAT model reproduced the nonlinear dose dependence for each of these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Note: Added in proof. Talinolol has been demonstrated to be a substrate for both human OATP1A2 and OATP2B1 in Xenopus oocytes (Ikumi Tamai, personal communication).

References

  1. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption, elimination, transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717–33.

    Article  PubMed  CAS  Google Scholar 

  2. Nakamura T, Yamamori M, Sakaeda T. Pharmacogenetics of intestinal absorption. Curr Drug Deliv. 2008;5(3):153–69.

    Article  PubMed  CAS  Google Scholar 

  3. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci. 2004;21(1):3–16.

    Article  PubMed  CAS  Google Scholar 

  4. Sai Y, Tsuji A. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today 2004;9(16):712–20.

    Article  PubMed  CAS  Google Scholar 

  5. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55(3):425–61.

    Article  PubMed  CAS  Google Scholar 

  6. Tsuji A. Transporter-mediated drug interactions. Drug Metab Pharmacokinet. 2002;17(4):253–74.

    Article  PubMed  CAS  Google Scholar 

  7. Sadee W, Drubbisch V, Amidon GL. Biology of membrane transport proteins. Pharm Res. 1995;12(12):1823–37.

    Article  PubMed  CAS  Google Scholar 

  8. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11–23.

    Article  PubMed  CAS  Google Scholar 

  9. Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res. 2005;22(10):1559–77.

    Article  PubMed  CAS  Google Scholar 

  10. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105.

    Article  PubMed  CAS  Google Scholar 

  11. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, et al. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006;318(1):395–402.

    Article  PubMed  CAS  Google Scholar 

  12. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425–46.

    Article  PubMed  CAS  Google Scholar 

  13. US FDA. Draft guidance for industry: drug interaction studies—study design, data analysis, and implications for dosing and labeling, U.S.D.o.H.a.H. services, editor; 2006. Rockville: Center for Drug Evaluation and Research.

  14. Yu LX, Amidon GL. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm. 1998;45(2):199–203.

    Article  PubMed  CAS  Google Scholar 

  15. Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res. 2006;23(8):1712–20.

    Article  PubMed  CAS  Google Scholar 

  16. Bolger MB, Haworth IS, Yeung AK, Ann D, von Grafenstein H, Hamm-Alvarez S, et al. Structure, function, and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1. J Pharm Sci. 1998;87(11):1286–91.

    Article  PubMed  CAS  Google Scholar 

  17. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(Suppl 1):S41–67.

    Article  PubMed  CAS  Google Scholar 

  18. Gonzalez-Alvarez I, Fernandez-Teruel C, Casabo-Alos VG, Garrigues TM, Polli JE, Ruiz-Garcia A, et al. In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results. Biopharm Drug Dispos. 2007;28(5):229–39.

    Article  PubMed  CAS  Google Scholar 

  19. Kwon H, Lionberger RA, Yu LX. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. Mol Pharm. 2004;1(6):455–65.

    Article  PubMed  CAS  Google Scholar 

  20. Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes. Drug Metab Dispos. 2003;31(12):1507–19.

    Article  PubMed  CAS  Google Scholar 

  21. Reigner BG, Couet W, Guedes JP, Fourtillan JB, Tozer TN. Saturable rate of cefatrizine absorption after oral administration to humans. J Pharmacokinet Biopharm. 1990;18(1):17–34.

    Article  PubMed  CAS  Google Scholar 

  22. Sinko PJ, Amidon GL. Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res. 1988;5(10):645–50.

    Article  PubMed  CAS  Google Scholar 

  23. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006;29(3–4):269–77.

    Article  PubMed  CAS  Google Scholar 

  24. Herrera-Ruiz D, Wang Q, Gudmundsson OS, Cook TJ, Smith RL, Faria TN, et al. Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues. AAPS PharmSci. 2001;3(1):E9.

    Article  PubMed  CAS  Google Scholar 

  25. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007;35(4):590–4.

    Article  PubMed  CAS  Google Scholar 

  26. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003;20(10):1595–9.

    Article  PubMed  CAS  Google Scholar 

  27. Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, et al. Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 2009;26:560–7.

    Article  PubMed  CAS  Google Scholar 

  28. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653–65.

    Article  PubMed  CAS  Google Scholar 

  29. Dave MH, Schulz N, Zecevic M, Wagner CA, Verrey F. Expression of heteromeric amino acid transporters along the murine intestine. J Physiol. 2004;558(Pt 2):597–610.

    Article  PubMed  CAS  Google Scholar 

  30. Sinko PJ, Balimane PV. Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos. 1998;19:209–17.

    Article  PubMed  CAS  Google Scholar 

  31. Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83(3):416–21.

    Article  PubMed  CAS  Google Scholar 

  32. Uchino H, Kanai Y, Kim do K, Wempe MF, Chairoungdua A, Morimoto E, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61(4):729–37.

    Article  PubMed  CAS  Google Scholar 

  33. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci. 1999;88(10):1067–72.

    Article  PubMed  CAS  Google Scholar 

  34. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15(8):1154–9.

    Article  PubMed  CAS  Google Scholar 

  35. Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003;306(2):778–86.

    Article  PubMed  CAS  Google Scholar 

  36. Balimane P, Sinko P. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm Drug Dispos. 2000;21(5):165–74.

    Article  PubMed  CAS  Google Scholar 

  37. Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res. 1998;15(9):1382–6.

    Article  PubMed  CAS  Google Scholar 

  38. Adson A, Burton PS, Raub TJ, Barsuhn CL, Audus KL, Ho NF. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci. 1995;84(10):1197–204.

    Article  PubMed  CAS  Google Scholar 

  39. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54(6):595–605.

    PubMed  CAS  Google Scholar 

  40. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39(12):2759–64.

    PubMed  CAS  Google Scholar 

  41. MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother. 2004;53(6):899–901.

    Article  PubMed  CAS  Google Scholar 

  42. del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci. 2008;35(3):161–74.

    Article  PubMed  CAS  Google Scholar 

  43. Madan J, Chawla G, Arora V, Malik R, Bansal AK. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J. 2005;7(1):E224–30.

    Article  PubMed  CAS  Google Scholar 

  44. Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J. 2002;21(4):580–9.

    Article  PubMed  CAS  Google Scholar 

  45. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85–96.

    Article  PubMed  CAS  Google Scholar 

  46. Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci. 2004;93(6):1628–40.

    Article  PubMed  CAS  Google Scholar 

  47. Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986;36(5):830–9.

    PubMed  CAS  Google Scholar 

  48. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40(2–3):123–7.

    Article  PubMed  CAS  Google Scholar 

  49. Gidal BE, DeCerce J, Bockbrader HN, Gonzalez J, Kruger S, Pitterle ME, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31(2):91–9.

    Article  PubMed  CAS  Google Scholar 

  50. Gordi T, Hou E, Kasichayanula S, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther. 2008;30(5):909–16.

    Article  PubMed  CAS  Google Scholar 

  51. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem. 1998;251(1–2):252–61.

    Article  PubMed  CAS  Google Scholar 

  52. de Mey C, Schroeter V, Butzer R, Jahn P, Weisser K, Wetterich U, et al. Dose–effect and kinetic–dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans. J Cardiovasc Pharmacol. 1995;26(6):879–8.

    Article  PubMed  Google Scholar 

  53. Tang H, Pak Y, Mayersohn M. P-glycoprotein (P-gp) mRNA and protein expression pattern along the small intestine of the Yucatan micropig. AAPS Annual Meeting. 2002. Toronto, Canada.

  54. Tang H, Pak Y, Mayersohn M. Protein expression pattern of P-glycoprotein along the gastrointestinal tract of the Yucatan micropig. J Biochem Mol Toxicol. 2004;18(1):18–22.

    Article  PubMed  CAS  Google Scholar 

  55. Naruhashi K, Sai Y, Tamai I, Suzuki N, Tsuji A. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. Pharm Res. 2002;19(10):1417–23.

    Article  PubMed  CAS  Google Scholar 

  56. Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F, et al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem. 1999;274(49):34948–54.

    Article  PubMed  CAS  Google Scholar 

  57. Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003;20(8):1200–9.

    Article  PubMed  CAS  Google Scholar 

  58. Korjamo T, Kemilainen H, Heikkinen AT, Monkkonen J. Decrease in intracellular concentration causes the shift in K m value of efflux pump substrates. Drug Metab Dispos. 2007;35(9):1574–9.

    Article  PubMed  CAS  Google Scholar 

  59. Gramatte T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther. 1996;59(5):541–9.

    Article  PubMed  CAS  Google Scholar 

  60. Trausch B, Oertel R, Richter K, Gramatte T. The protein binding of talinolol. Pharmazie 1995;50(1):72.

    PubMed  CAS  Google Scholar 

  61. Trausch B, Oertel R, Richter K, Gramatte T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos. 1995;16(5):403–14.

    Article  PubMed  CAS  Google Scholar 

  62. Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm. 2006;3(6):686–94.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA

    Michael B. Bolger, Viera Lukacova & Walter S. Woltosz

  2. 6 6th Street, Petaluma, California, 94952, USA

    Michael B. Bolger

Authors
  1. Michael B. Bolger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Viera Lukacova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Walter S. Woltosz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael B. Bolger.

Additional information

Guest Editors: Lawrence X. Yu, Steven C. Sutton, and Michael B. Bolger

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolger, M.B., Lukacova, V. & Woltosz, W.S. Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine. AAPS J 11, 353–363 (2009). https://doi.org/10.1208/s12248-009-9111-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-009-9111-6

Key words

Search

Navigation